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Abstract
Cerebral small vessel disease (SVD) is a common global brain disease that causes cognitive impairment, ischemic or hemorrhagic
stroke, problems with mobility, and neuropsychiatric symptoms. The brain damage, seen as focal white and deep grey matter lesions
on brain magnetic resonance imaging (MRI) or computed tomography (CT), typically accumulates “covertly” and may reach an
advanced state before being detected incidentally on brain scanning or causing symptoms. Patients have typically presented to
different clinical services or been recruited into research focused on one clinical manifestation, perhaps explaining a lack of
awareness, until recently, of the full range and complexity of SVD.
In this review, we discuss the varied clinical presentations, established and emerging risk factors, relationship to SVD features on
MRI or CT, and the current state of knowledge on the effectiveness of a wide range of pharmacological and lifestyle interventions.
The core message is that effective assessment and clinical management of patients with SVD, as well as future advances in diagnosis,
care, and treatment, will require a more “joined-up”’ approach. This approach should integrate clinical expertise in stroke
neurology, cognitive, and physical dysfunctions. It requires more clinical trials in order to improve pharmacological interventions,
lifestyle and dietary modifications. A deeper understanding of the pathophysiology of SVD is required to steer the identification of
novel interventions. An essential prerequisite to accelerating clinical trials is to improve the consistency, and standardization of
clinical, cognitive and neuroimaging endpoints.
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Introduction
Cerebral small vessel disease (SVD) is a global brain disease
affecting multiple clinical domains by disrupting normal
function of the perforating cerebral arterioles, capillaries,
venules, and brain parenchyma, manifesting on magnetic
resonance imaging (MRI) as white matter hyperintensities
(WMH), small subcortical infarcts, microinfarcts, lacunes,
enlarged perivascular spaces (PVS), microbleeds, superficial
siderosis, intracerebral hemorrhage (ICH), and atrophy.[1,2]
The core clinical manifestations include lacunar ischemic
stroke, intracerebral hemorrhage and cognitive decline,
including vascular cognitive impairment and amplification
of pathological and cognitive Alzheimer’s disease manifes-
tations.[3-5] There is increasing recognition that its
multidomain involvement extends beyond stroke and
dementia [Figure 1] to include gait and balance dysfunction,
behavioral and neuropsychiatric symptoms, and subtle,
non-focal neurological features [Figure 2],[6-8] resulting in
presentations to diverse general and specialist services
[Table 1].
The onset of sporadic SVD typically occurs during mid to
late life and although the disease, its associated risk factors,
and clinical features such as gait dysfunction and cognitive
decline are more prevalent with advancing age, these are
not just inevitable consequences of ageing. SVD often
arises on a background of other complex comorbidities,
and untangling SVD symptoms from those attributable to
other conditions requires careful clinical judgment includ-
ing neuroimaging review. Adopting a more integrated,
holistic approach to identifying early and intermediate
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clinical brain damage markers is essential to permit
prognostication, supportive management strategies, iden-
tification of patients for emerging treatment trials, and
future refinement of targeted prevention and management
strategies.
Here we present an evidence-based overview of the
literature on clinical aspects of SVD, discussed in the
context of our clinical and research experience of caring for
these patients.
Methods for Searching, Identifying, Selecting, and
synthesizing Data
We searched Ovid MEDLINE using the terms “Cerebral
Small Vessel Diseases/” or “White matter hyperintens∗”
and “Clinical” from inception to April 3, 2020. We
separately searched “Lacunar state” or “Binswanger”. On
risk factors for SVD and its progression, we searched Ovid
MEDLINE using the terms “Cerebral small vessel disease”
OR “White matter hyperintens∗” AND “vascular risk
factor” OR “risk factor” AND “disease progress∗” OR
“outcome” up to June 5th 2020. On therapeutic
approaches to SVD, we searched Ovid MEDLINE using
the terms “Cerebral small vessel disease” OR “White
matter hyperintense∗” OR “lacunar” OR “vascular
cognitive impairment” up to 12th May 2020. We
supplemented the electronic search with the authors’
personal files and searched reference lists of identified
papers. We screened 2169 papers for clinical diagnosis,
1094 for risk factors and progression, and 7695 for
interventions in SVD, including the most relevant papers
reporting SVD associations.
Defining the Natural History of Clinical Cerebral Small
Vessel Disease
The earliest clinicopathological reports by Binswanger[9] in
1894, based on eight post-mortem cases, described
“encephalitis subcorticalis chronica progressiva”, charac-
terized pathologically by pronounced white matter atro-
phy and cortical thinning and clinically by a progressive,
fluctuating course, arising predominantly in males in their
50s, characterized by chronic cognitive and emotional
symptoms, and occasionally punctuated by acute hemiple-
gic episodes.
In 1901, Marie[10] described ‘l’état lacunaire’ or “the
lacunar state”, involving one or more lacunes on
neuropathology, characterized by progressive neurological
Figure 1: Case vignette. A 75-year-old female presents to the acute medical assessment unit with recurrent falls. She has a past medical history of hypertension, hypercholesterolaemia
and recent lacunar stroke 3 months ago. She is an ex-smoker of 40 pack-years. On examination her blood pressure is 169/85 mmHg, without postural hypotension, and pulse is regular. She
is objectively apathetic and mildly bradyphrenic. She has a slow, shuffling gait, with preserved arm swing, and is unsteady on initiation and turning. She has mild dysarthria and a left
pronator drift. She scores 22/30 on MoCA, with deficits in executive function, attention and abstraction. Her daughter reports progressive cognitive and functional decline over the past 2
years and subtle behavioural changes developing over the past month: she has become apathetic, finds it increasingly difficult to manage her finances, and is easily fatigued performing
minor household tasks. Full blood count, urea and electrolytes, and C-reactive protein are normal, serum cholesterol is 5 mmol/L, HbA1c is 40 mmol/mol and electrocardiogram shows sinus
rhythm, normal conduction intervals, and mild left ventricular hypertrophy. Brain MRI shows a subacute right thalamic small subcortical infarct, periventricular and deep white matter
hyperintensities, enlarged perivascular spaces, and a chronic lacune: (A) Subacute small subcortical infarct in the right thalamus (yellow arrow, on FLAIR) relating to clinical lacunar stroke
three months ago and white matter hyperintensities (hyperintense on FLAIR); (B) Lacunes and enlarged perivascular spaces (blue and red circles respectively, hyperintense on T2-weighted
imaging. MoCA: Montreal cognitive assessment scale; MRI: Magnetic resonance imaging; FLAIR: Fluid-attenuated inversion recovery.
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Figure 2: Clinical features of small vessel disease.
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decline, episodes of mild hemiparesis, and later, dysarthria,
marche à petit pas (gait with little steps), imbalance,
incontinence, pseudobulbar signs, and dementia.
Much remains unknown about its precise natural clinical
history: the disease is elusive in its early stages unless the
patient has overt symptoms that are easily recognized from
the current neurological lexicon for stroke or dementia
[Figure 3]. Proposed pathophysiological mechanisms
underlying SVD are outside the scope of this review but
are described in detail elsewhere.[2,11,12] We describe acute
and chronic clinical and neuroimaging manifestations at
various SVD stages.
Modes of presentation
“Silent” small vessel disease
“Silent” or “covert” SVD refers to disease incidentally
detected on neuroimaging without the patient apparently
having overt symptoms. While some lesions are truly
clinically silent, for instance if small or located in less
eloquent regions,[13] careful questioning about historical
stroke or transient ischemic attack (TIA) symptoms is
recommended, as a positive history may render such
individuals eligible for secondary stroke prevention.[14]
Furthermore, a comprehensive history and examination,
including collateral history from an informant, may yield
more subtle, associated features such as apathy, abrupt or
insidious cognitive decline, fatigue or gait disturbances that
do not necessarily meet diagnostic criteria for stroke or
dementia but have been linked temporally with acute
lesions on Diffusion-Weighted Imaging (DWI)MRI (n= 6/
649 community sample, n= 10/30 vascular dementia
population).[7,15] How patients report, and clinicians
interpret, these symptoms is poorly understood and
inter-individual factors influencing accurate reporting
are complex. For instance, a “threshold effect” of sufficient
SVD burden might accumulate before triggering symp-
toms[16] and this might vary between individuals and at
different ages [Figure 4]. Similarly, physical reserve is likely
to play a role: the fitter an individual, the more
compensatory mechanisms can be employed despite
accumulating deficits. Whether initially silent infarcts
due to SVD are clinically “unmasked” later by increasing
SVD burden and/or increasing physical frailty, revealing
delayed typical or atypical symptoms, is a target for future
research.
Subtle neurological symptoms
To uncover whether “non-stroke” symptoms may be
associated with acute infarcts on brain imaging, some
studies have focused on transient neurological attacks
(TNAs). Almost one-quarter of TNA patients (n = 13/56)
have corresponding DWI hyperintense lesions.[8] More-
over, both TNAs and Transient Focal Neurological
Episodes, a subset of TNAs typified by spreading,
recurrent, stereotyped episodes and associated with
cerebral amyloid angiopathy (CAA),[17] herald a higher
risk of future ischemic and hemorrhagic stroke, while
TNAs also associate with chronic SVD features and
Table 1: Diverse presentations: clinical small vessel disease encounters with general and specialist services
Clinical service Presenting symptoms
General practitioner All below presentations + informant reports of altered behavior, deteriorating cognition and
function
Physiotherapist Deteriorating mobility, falls
Speech and language therapist Dysphagia, dysarthria
Occupational therapist Functional decline requiring social support
Geriatric medicine service
∗
Inpatient admissions including unexplained falls, gait deterioration, delirium +/– obvious
precipitant, stroke, functional and cognitive decline
Falls clinics
Parkinson’s disease clinics
Day hospital and rehabilitation
Dementia clinics
Residential and nursing home assessments
Stroke service
∗
Stroke, transient ischaemic attacks, transient neurological attacks
Neurology service
∗
Stroke, transient neurological attacks, cognitive assessment clinics, referrals for declining
mobility, Parkinson’s disease, pseudobulbar palsy
Psychiatry service
∗
Dementia clinics: cognitive impairment diagnosis, management of behavioral and
psychological symptoms of dementia
Mood and personality changes




Falls, delirium, acute neurological symptoms including stroke
Acute medical assessment unit
and General internal medicine
∗
Acute neurological symptoms including stroke, falls, delirium
Orthopedic service
Osteoporosis service
Falls resulting in fractures
∗
Services with readily available access to neuroimaging investigations.
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dementia.[4,18,19] Other neurological symptoms associated
with SVD include dysphagia,[20] dysarthria,[21] pyramidal
tract signs, and pseudobulbar palsy.[22]
Neuropsychiatric symptoms
Neuropsychiatric symptoms are common post-stroke and
in individuals with vascular dementia, but whether there is
a shared neuroanatomical substrate remain unclear and
longitudinal studies are sparse. More severe WMH are
associated with apathy, fatigue, and delirium but not
subjective memory complaints or anxiety (submitted).
There is inadequate evidence to determine whether other
symptoms including delusions or emotional lability are
associated with SVD due to insufficient data and mixed
approaches to symptom assessments.
Figure 3: Defining the trajectory of small vessel disease. MCI: Mild cognitive impairment.
Figure 4: Factors influencing reporting of symptoms related to disease accumulation.
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Future research should target whether emotional liability,
delusions, and other neuropsychiatric symptoms relate to
disease severity including progression.
Whether depression contributes to, or results from, SVD is
unclear. Further pathological, clinical, and imaging
relationships need investigation, focusing on interactions
with shared vascular risk factors, medications, treatment
resistance, neurotransmitter alterations, and associations
with cognitive impairment.[23]
Lacunar stroke presentations
Lacunar stroke clinical syndrome (LACS) is a key SVD
manifestation.[3] While specific syndromes including pure
motor/hemisensory stroke and ataxic hemiparesis are more
strongly associated with acute small subcortical infarcts,[24]
LACS classification is imprecise[24,25] and one-third of minor
strokes are not accompaniedbya corresponding acute infarct
radiologically, even on the most sensitive diffusion MRI
(n= 264).[26] Non-lacunar pathology, for example, cortical
infarcts, may manifest as LACS and conversely, small
subcortical infarcts may present with other non-LACS
syndromes[25,27] in around 15% to 20% (n= 137), or
develop silently.[13] While some LACS may masquerade as
cortical stroke syndromeswhen the responsible brain lesion is
close to the cortex,[27] or in specific locations such as the
thalamus. Other cases where LACS and partial anterior
circulation stroke (PACS) are confused may simply reflect
disappearance of, or failure to recognize, cortical symptoms,
mistaking dysarthria for dysphasia, or overlooking visual
field defects.[25] Furthermore, other comorbidities may alter
or obscure stroke presentations [Figure 4], for example, a
patient with arthritis and peripheral neuropathy may not
notice an ataxic hemiparesis.
Associated short-term with infarct growth (n= 61)[28] and
poor functional outcomes (n= 4011)[29] in stroke, SVD
effects outlast the acute phase, contributing increased risk
long-term of recurrent ischaemic stroke, disability, demen-
tia, and death (n= 71,298).[30]
Mobility and movement
Gait and balance dysfunction, shortened stride length
(n= 431),[6] unexplained dizziness (n= 122),[31] falls
(n= 187),[32] and features of vascular parkinsonism such
as bradykinesia, rigidity, and gait disturbances (n= 503
community-dwelling)[33] are all associated with SVD.
Urinary symptoms
Eight studies, mostly in older community dwelling-
subjects, detected urinary symptom associations with
WMH (total n= 1944),[34-41] while two did not
(n= 648).[42,43] These findings need to be reproduced in
large prospective blinded studies, adjusting for mobility,
frailty and co-morbidities.
Vascular cognitive impairment: clinical features
Vascular cognitive impairment (VCI) is a broad term,
encompassing mild cognitive impairment and dementia.
We focus on the clinically sensitive DSM-V diagnostic
criteria,[44] which require evidence of cognitive decline
from a previous performance level in one or more domains
including: (a) concern about decline from a patient,
knowledgeable informant or clinician, and (b) objective
impairment or decline on testing. To establish a vascular
etiology, either a temporal association with stroke/s or
prominent decline in complex attention/processing speed
and frontal-executive functions is required, although it is
increasingly apparent that SVD is not confined to specific
domains,[45] in contrast to previous thinking that focused
on domain-specific impairments. Further discrimination
between mild cognitive impairment and dementia is based
on whether cognition is sufficiently impaired to result in
loss of functional independence.[44] This may be described
by either patient or informant, e.g. non-specific reports of
“not managing at home” or deficits in instrumental
activities of daily living, e.g. inability to independently
manage one’s finances. Clinicians frequently rely on the
informant account, which is invaluable, as many individ-
uals with cognitive impairment lack insight or minimise
their symptoms.
Distinguishing the subcortical subtype of vascular
cognitive impairment
The small vessel contribution to dementia exceeds that of
large vessel disease, with incident lacunes thought to herald
the highest dementia risk at least in community-dwelling
subjects.[46] Cognitive features include slow thought
processing, poor memory retrieval, and executive dysfunc-
tion.[47] The subcortical vascular cognitive impairment
(VCI) subtype is supported by symptoms such as impaired
problem-solving, personality changes including apathy,
mood disorders, pseudobulbar palsy, dysarthria, subtle
sensory and motor deficits, urinary symptoms, and gait
deterioration including postural instability.[47,48] Although
these clinical symptoms are frequently cited as subcortical
VCI features, many of these correlations are based on
older, small, clinicopathological and CT-based studies.
There is a scarcity of MRI studies confirming these
associations in VCI populations, with recent studies’ main
clinical focus on cognitive tests and vascular risks. Abrupt
cognitive impairment due to single strategic small
subcortical infarcts has been described rarely,[47] is
understudied, and requires further characterization.
The neurological examination provides clues to subtyping
VCI: subtle abnormalities including dysarthria, dysphagia,
and parkinsonian, rather than hemiplegic gait, are all more
prevalent in subcortical vascular dementia (n= 706).[22]
Subcortical may also be differentiated from cortical VCI
and Alzheimer’s disease by the absence of aphasia,
apraxia, agnosia, amnesia, and hemianopia[48] although
cortical and subcortical lesions, with or without Alz-
heimer’s disease, frequently coexist so the specificity of
these symptoms will be limited. Supportive findings on
neuroimaging raise diagnostic certainty from possible to
probable when there is no clear temporal relationship to
stroke events,[44] although the extent of radiological SVD
considered sufficient to contribute to a VCI diagnosis is
debated.[49] Neuroimaging is particularly important for
distinguishing SVD-related VCI, where stepwise cognitive
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decline is often absent, instead characterized by insidious,
fluctuating cognitive decline, punctuated by neurological
deficits [Figure 3].[48]
Function
SVD substantially limits independence, contributing to
functional impairment,[29] stroke recurrence, dementia,
and mortality after stroke,[30] as well as functional decline
and mortality in non-disabled adults.[50] SVD is associated
with longer hospital lengths of stay in cognitively
impaired,[51] and earlier institutionalization in stroke
patients.[52]
Recommended approaches to patients presenting with the
SVD syndrome
Many clinical features described in this review are non-
specific when considered in isolation. However, clinical
presentations are frequently multifactorial, particularly in
older people in whom SVD is highly prevalent [Table 1].
When faced with these features in combination, supported
by previous neuroimaging, and especially in individuals
with a history of lacunar stroke or cognitive impairment,
one should consider SVD presence and/or progression as a
contributor.
Risk Factors for SVD and its Progression
Risk factors for progression in SVD include “traditional
vascular risk factors” such as age and hypertension, and
MRI biomarkers, which not only represent the cornerstone
for SVD diagnosis but also identify risk of progression,
provide a feasible strategy for monitoring patients, and a
therapeutic target.
Vascular risk factors
Several vascular risk factors are associated with SVD, but
the two major ones are advancing age and hyperten-
sion.[50,53] Specifically, In community-based samples,
WMH prevalence was low before 55 years of age but
increased sharply with age thereafter, from 11% to 21% in
the subjects 64 years of age on average to 94% in
individuals 82 years of age on average.[14] Cerebral
microbleeds (CMB), CAA, PVS and lacunes also increase
with age.[17,50,54-56]
The most important modifiable vascular risk factor for
SVD is arterial hypertension (defined as blood pressure
greater than 140/90 mmHg).[57] Ambulatory blood
pressure (BP) provides more accurate data on BP status
than office-based BP measurements and may help BP
control in patients with extensive SVD.[58] In addition,
abnormal circadian BP variations during sleep, specifically
non-dipping (<10% fall in nocturnal BP) and reverse-
dipping patterns (rise in nocturnal BP) are associated with
WMH.[59] Hypertension is also associated with CMBs in
adults with and without established cerebrovascular
disease.[60] SVD lesions can occur in individuals without
hypertension,[61] plus recent data from large consortia
genetic analyses indicate that some patients with more
severe SVD may be particularly sensitive to any BP
elevation (in press). Since it is currently difficult to identify
individuals whose small vessels may be particularly
sensitive to even minor BP elevations, it remains uncertain
how intensively blood pressure should be lowered.[50]
Diabetes mellitus types 1 (relative ratio [RR] 7.2, 95%
confidential interval [CI] 3.2–16.1) and 2 (RR 2.8, 95%CI
2.3–3.5) are associated with lacunar infarction[62] and
other biomarkers of SVD on MRI, including atrophy[63]
and CMBs.[60] Because the duration of diabetes is
important in determining ischemic stroke risk, early onset
of type 1 diabetes confers a cumulatively higher lacunar
stroke risk in such patients. Furthermore, fasting glucose
level (odds ratio [OR] 1.27, 95% CI 1.10–1.46) and high
insulin resistance scores (OR 1.33, 95% CI 1.05–1.68) are
also associated with increased incident lacunes.[54] People
with type 2 diabetes have a 1.5 times increased risk of
dementia, and high HbA1c, concentration and glucose
variability are negatively associated with cognitive func-
tion.[63] Interestingly, type 2 diabetes is associated with a
greater increase in depressive symptoms, which SVD may
contribute to.[23,64]
Additionally, metabolic syndrome is associated with silent
brain infarction and incident lacunes.[53,54] The potential
impact of dyslipidemia remains uncertain. In the athero-
sclerosis risk in communities (ARIC) study, high triglyc-
erides increased the risk of incident lacunes (OR 1.24, 95%
CI 1.04–1.47), while elevated high-density lipoproteins
(HDL) reduced the risk (OR 0.77, 95% CI 0.59–0.99).[65]
Moreover, the use of lipid-lowering medications was
associated with fewer incident lacunes (OR 0.15, 95% CI
0.04–0.61) in an observational study,[55] but higher total
(OR 1.67, 95% CI 1.20–2.31) and lobar (OR 1.52, 95%
CI 1.02–2.27) CMB presence in a separate community-
based study.[66] In contrast, lower HDL may predict
WMH volume increase in people aged between 73 and 76
years[67] so the relationship between HDL and SVD needs
further research.
Lifestyle risk factors
Regular exercise, healthy diet (Mediterranean diet, folic
acid and vitamin B12),[68] and avoiding adverse lifestyle
factors such as smoking, excess alcohol or high dietary
sodium, are all associated with having fewer SVD features
in observational studies.[69-71] Alcohol intake is associated
with worse WMH in patients with minor stroke.[72] High
dietary sodium (>5 g/d) increases stroke risk (crucially
lacunar stroke) and worsens WMH and total SVD
burden.[68,69] Disappointingly, a subsequent systematic
review of lifestyle interventions including exercise did not
slow cognitive decline.[73]
Sleep dysfunction is an important and so far largely
overlooked risk factor for adverse brain health. Whether
unusual sleep patterns increase the risk of SVD lesions is
unclear although disordered night-time sleep is associated
with brain atrophy and increased daytime sleep is
associated with increased PVS on MRI.[74] Abnormal
sleep, such as obstructive sleep apnea, may be associated
with more WMH and silent lacunar infarction,[75]
although inability to correct for co-associated factors like
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smoking and hypertension may have overestimated the
association.
Environmental, lifetime, and cultural risk factors
Genetic, environmental/lifestyle and cultural risk factors
are likely related to SVD burden and to its associated
outcomes such as cognitive impairment.[54] Data are
currently unclear onmale-female differences, and apparent
differences may reflect age or recruitment bias, rather than
a true difference in SVD burden, However, some hospital-
based studies suggest that males have a higher burden of
both sporadic[70] and monogenic SVDs,[71] but further
research is needed to differentiate any true male-female
difference in incidence or severity and the reasons behind
any difference observed.
Regarding ethnic or geographical differences, it is difficult
to disentangle effects of socioeconomic, dietary and
medical histories, and use of different protocols, from
true ethnic or geographical differences in the prevalence of
SVD.[76]
Brain and cognitive reserves in later life are influenced by
lifetime experiences, including those early in life.[77] Early
life exposures could explain some of the variation between
SVD and cognitive function2 and include childhood
cognitive ability, with lower cognitive ability in childhood
being associated with increased total WMH scores (r= –
0.07, 95% CI, –0.12 to –0.02, I2= 0%) in later life.
Similarly, adverse childhood socioeconomic status (SES)
increases the risk of worse deep (r= –0.181) and
periventricular (r= –0.146) WMH, and lower educational
attainment is associated with more WMH in later life (OR
1.24; 95% CI, 1.05–1.47). The trends were similar for
other SVD markers although sample sizes were not large
enough to determine if similar associations are present for
other SVD markers.[77] Consistent with this, in patients
presenting with minor stroke, premorbid intelligence
quotient (IQ) and educational attainment predict post-
stroke cognitive impairment more than stroke severity or
vascular risk factors.[72]
Use of brain imaging appearances to predict risk of SVD
progression
The lesions seen on MRI adopted as biomarkers of SVD
include recent small subcortical (or lacunar) infarct (RSSI),
WMH, lacune, CMB, visible PVS, and cerebral atro-
phy.[78] All of these lesions have been associated with
dysfunction of the cerebral small vessels when measured in
patients using MRI, including blood-brain barrier leakage,
impaired cerebral vasoreactivity and increased vascular
pulsatility, reflecting impaired endothelial function and
related effects on the glia and neurons.[2] These lesions are
individually and collectively associated with increased risk
of stroke, cognitive decline and dementia, and poor
functional outcomes after stroke, and are highly herita-
ble.[29,30,50,79]
The single strongest risk factor for SVD lesion progression
identified so far is having a severe SVD lesion burden at
presentation.[2] Potential advances in neuroimaging of
SVD based on MRI, e.g. diffusion tensor imaging (DTI)
metrics such as fractional anisotropy (FA) and mean
diffusivity (MD), show promise in research for detecting
early white matter damage and may in future become
widely used clinical applications.[80]
Although SVD lesions were previously considered to be
“focal” and “permanent”, it is now clear that they
represent more dynamic global disease. Thus, WMH
progression is worse in those with increased baseline
WMH volume,[81,82] and worsening WMH burden
associates with brain atrophy including cortical thin-
ning.[83] Since WMHmay have some clinically meaningful
reversible components,[81,82] the concept that prevention
of worsening WMH-related brain damage may translate
into long-term benefits for brain health is important.
Since the common SVD lesions are mostly visible on
routine clinical brain MRI and computed tomography
(CT) scanning (excluding CMB and PVS), greater use
could be made of their potential for predicting prognosis.
Several MRI scoring systems can be easily applied by
clinicians to characterize SVD severity, many of which can
predict clinical outcomes. The Fazekas scale is commonly
used to evaluateWMH onMRI and can be used on CT.[78]
Similarly, while less sensitive than MRI-based scores,
equivalent CT-based scores for total SVD and “brain
frailty”[29] predict poor functional outcome and cognitive
impairment after stroke.[29,30] A simple and pragmatic
score that may provide a more complete estimate of the full
impact of SVD on the brain is the total SVD score
(counting the presence of WMH, lacunes, CMB, and PVS
on MRI as an ordinal score of 0 to 4), which could have
potential for patient risk stratification.[70] Despite the
increasing availability of MRI and limitations of CT, CT
continues to be the most widely used neuroimaging tool in
patients with neurological or neuropsychiatric symptoms,
and can provide valuable information for SVD assess-
ment.[29]
Therapeutic Approaches
Given the chronic nature and insidious progression of
SVD, potential treatments will likely be required over the
longer term as is done for the secondary prevention of
vascular diseases. Due to the worldwide prevalence of SVD
and association with increasing age, potential therapeutic
agents will need to be affordable, easy to administer, safe,
simple and have limited drug-drug interactions.[84,85]
Currently, there is considerable variability in selection
and definitions of end-points for SVD trials including of
imaging endpoints and clinically relevant magnitudes of
change, cognitive and functional outcomes, recurrent
stroke, bleeding, and death. Hence, we report several
outcomes depending on available data.
Lifestyle interventions
Lifestyle and behavioral interventions may have potential
benefit in patients with SVD and are currently under
investigation [Table 2]. Two trials have assessed aerobic
exercise and found no difference in WMH volume[86,87]
but did demonstrate improved cognitive scores at 6months
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Table 2: Therapeutic approaches for SVD.





70 patients with WMH and
cognitive impairment
98 patients with subjective memory
problems or mild cognitive
impairment and at least 1 vascular
risk factor
No difference in WMH volume in
substudy (n= 30), but improved
cognitive scores at 6 months
No difference in WMH volume at 2
years
Resistance training RCT
NCT00426881[89] 54 patients with WMH but no
cognitive impairment
Reduced WMH volume at 12
months
Smoking Observational study




264 patients with stroke




- SVD burden on imaging
- risk of stroke and dementia
- rate of cortical thinning
Dietary sodium Observational study
MSS-2[69] 264 patients with stroke High dietary sodium increased risk
of: lacunar > cortical stroke,








42,234 patients with lacunar stroke
3020 patients with lacunar stroke
254 patients with spontaneous ICH
taking antithrombotic therapy
Single antiplatelet therapy reduced
recurrent stroke across 17 trials.
Chronic aspirin + clopidogrel vs.
aspirin stopped early due to excess
bleeding and death in dual
antiplatelet group
Single antiplatelet therapy vs.
avoiding antiplatelet therapy did
not increase hazard of recurrent









3020 patients with lacunar stroke
454 hypertensive patients with
WMH
111 hypertensive patients with
lacunar stroke and established
SVD
Less WMH progression with
intensive BP reduction.
No difference in recurrent stroke or
long-term cognition with intensive
BP lowering
Less progression of WMH but no
difference in brain volume over 4
years with intensive vs. standard
BP treatment
No difference in white matter
damage on DTI with intensive vs.
standard BP lowering. CBF did
not fall with BP reduction in a







20,536 patients with vascular risk
factors
208 patients with TIA
5804 patients with vascular risk
factors
81 patients with stroke and pre-
stroke statin
Simvastatin did not influence
cognitive outcomes
Simvastatin did not influence WMH
progression
Pravastatin did not influence
cognitive function (n= 5804) or
WMH progression (n= 535)
Less WMH progression with pre-
stroke statin
(continued )
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in those randomized to aerobic exercise as compared with
those receiving usual care.[88] In a subgroup of a small trial
(n= 54), resistance training was associated with reduced
WMH volume at 12 months as compared with twice-
weekly balance and tone exercises.[89] Several ongoing
trials intend to build upon this data.
Smoking is strongly associated with an increased burden
of SVD and cortical loss in observational studies,[70,71,90]
and therefore, smoking cessation should be strongly
encouraged.
High dietary sodium was associated with increased stroke,
particularly lacunar events, WMH and SVD burden in
patientswith stroke[69] andwith risk of stroke in population
studies.[91] Trials assessing the effect of dietary sodium in
SVD are lacking, as they are for other vascular disease, but
reduction in dietary salt is good general health advice.
Encouragingly, exercise and a healthy Mediterranean diet
with folic acid and vitamin B12, combined with guideline
basedvascular risk reduction (ie,multidomain intervention),
slowed cognitive decline in older people at risk of dementia
compared with vascular risk factor reduction alone.[92]
Traditional stroke prevention treatments
Antiplatelet medication
Single antiplatelet therapy reduced recurrent stroke as
compared with no antiplatelet agent in a meta-analysis of
17 trials totaling 42,234 patients with previous lacunar
Table 2
(continued).
Intervention Study type Population Notes





10,449 patients with ischaemic
stroke
57 patients with lacunar stroke
Patients with lacunar stroke (target
400)
Cilostazol reduced recurrent stroke
(ischaemic and haemorrhagic)
particularly in trials with larger
populations of lacunar stroke
patients.
Cilostazol was associated with less
WMH progression
Effect of cilostazol on recurrent
stroke, death and dependency,






4011 patients with stroke
57 patients with lacunar stroke
Patients with lacunar stroke (target
400)
GTN given under 6 hours of onset
(n= 273) was associated with
improved clinical outcomes at 90
days
Pilot trial of ISMN on
cerebrovascular reactivity
Effect of ISMN on recurrent stroke,
death and dependency, cognition
and imaging SVD markers
Vitamins RCT Substudy
VITATOPS[112] 359 patients with stroke Vitamin B supplements for 2 years
in patients with severe WMH had
slower WMH progression
Allopurinol RCT
XILO-FIST (NCT02122718) Patients with ischaemic stroke
(target 464)
Effect of Allopurinol on recurrent
stroke and WMH progression
RIC
RIC RCT
Wang et al[113] 30 patients with SVD RIC twice daily for 1 year reduced
WMH and improved visuospatial
and executive function
AIBL: Australian Imaging Biomarkers and Lifestyle study; BP: blood pressure; CADASIL: Cerebral autosomal dominant arteriopathy with subcortical
infarcts and leukoencephalopathy; CBF: cerebral blood flow; CMB: cerebral microbleeds; DTI: diffuse tensor imaging; ENOS: Efficacy of Nitric Oxide in
Stroke Trial; GTN: glyceryl trinitrate; ICH: intracerebral haemorrhage; ISMN: isosorbide mononitrate; LACI-1/2: LACunar Intervention Trial -1 or 2;
MSS-2:Mild Stroke Study-2; NO: Nitric oxide; PRESERVE is the name of a trial, it is not an acronym; PROSPER: Prospective Study of Pravastatin in the
Elderly at Risk; RCT: randomised controlled trial; RESTART: Restart or Stop Antithrombotics Randomised Trial; RIC: Remote ischaemic conditioning;
ROCAS: Regression of Cerebral Artery Stenosis study; SPRINT-MIND: Systolic blood PRessure INtervention Trial-MIND; SPS3: Secondary Prevention
of Small Subcortical Stroke Trial; SVD: small vessel disease; VITATOPS: VITAmins TO Prevent Stroke; WMH: white matter hyperintensities; XILO-
FIST: Xanthine oxidase Inhibition for the Improvement of Long-term Outcomes Following Ischaemic Stroke and Transient ischaemic attack.
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ischemic stroke.[93] The secondary prevention of small
subcortical stroke (SPS3) trial randomized 3020 patients
with a symptomatic lacunar stroke to chronic aspirin and
clopidogrel versus aspirin alone and was stopped early due
to excess bleeding and death in the dual antiplatelet
group.[94] In observational studies, antiplatelet therapy has
been associated with prevalent CMBs (OR 1.21; 95% CI
1.07–1.36)[95] while anticoagulants have been associated
with prevalent and incident CMBs (OR 1.72, 95% CI
1.22–2.44; I2= 19%).[96] Given the shared pathophysiol-
ogy between CMB and ICH, the use of antiplatelet and
anticoagulant therapy in the presence of CMB remains
under study. A subgroup analysis from the randomized,
controlled RESTART trial reported that individuals with a
history of ICH taking antiplatelets in the presence of CMB
did not experience increased hazard (hazard ratio [HR]
0.30, 95% CI 0.08–1.13 vs. 0.7, 95% CI 0.13–4.61).[97]
Further randomized trials are needed to establish which
treatments are beneficial or harmful to CMBs and ICH,
both in stroke and non-stroke populations.
BP lowering
Intensive lowering of BP (<120 mmHg) in a subgroup
(n= 454) of the large Systolic blood PRessure INtervention
Trial (SPRINT) with WMH was associated with reduce
WMH progression and decreased risk of mild cognitive
impairment (HR 0.81; 95% CI 0.69–0.95) but no
difference in brain volume neither risk of dementia over
a 4 year period compared with standard BP manage-
ment.[100] Similarly, a meta-analysis of trials including
1,369 patients with prior stroke found less WMH
progression (standardized mean difference –0.19; 95%
CI –0.32 to –0.06; I2= 20%) with intensive BP lowering as
compared with usual care.[58] The SPS3 trial also assessed
intensive BP reduction but, in patients with prior lacunar
ischemic stroke specifically, found reduced hemorrhagic
stroke, however no difference in stroke recurrence[98] or
long-term cognition[99] with intensive compared with
standard BP lowering. In the PRESERVE trial, 111
hypertensive patients with lacunar ischemic stroke and
established SVDwere randomized to intensive BP lowering
(<125 mmHg) vs. standard care and demonstrated no
difference in white matter damage on diffusion tensor
imaging,[101] while in a further subgroup cerebral blood
flow was not compromised by intensive BP lowering.[102]
Lipid lowering
Unfortunately, there are no trial data pertaining to statins
exclusively in lacunar stroke. The SPARCL trial revealed
that atorvastatin reduced stroke recurrence in separate
subgroups of patients with large artery atherosclerotic
stroke and those with lacunar ischemic stroke.[114]
The effect of statins on other outcomes specific to SVD
have had mixed results to date. Simvastatin did not
influence cognitive outcome in the Heart Protection Study
(n= 20,536),[103] nor WMH progression in the ROCAS
study,[115] whilst pravastatin did not impact cognitive
function (n= 5804) or WMH progression (n= 535) in the
PROSPER study.[105] In contrast, patients with stroke and
severeWMHhad less progression ofWMH if they were on
a statin pre-stroke in the VITATOPS study.[106]
Pharmacological agents under investigation
Cilostazol
Cilostazol, a phosphodiesterase 3’ inhibitor, is commonly
used for stroke prevention in the Asia-Pacific region. As
well as its weak antiplatelet effects, cilostazol may be
beneficial in preventing SVD accumulation through
endothelial stabilization,[116] myelin repair,[117] neuro-
protective and anti-inflammatory mechanisms.[118] A
meta-analysis including 10,449 patients with prior ische-
mic stroke, predominantly from the South Asian-Pacific
region, found that cilostazol reduced recurrent ischemic
stroke (OR 0.68, 95% CI 0.57 to 0.81), intracerebral
hemorrhage (OR 0.43, 95% CI 0.29 to 0.64), and death
(OR 0.64, 95% CI 0.49 to 0.83) as compared with either
placebo, aspirin or clopidogrel.[107] When given longer
term (>6 months), cilostazol reduced recurrent ischemic
stroke to a greater degree than when given short-term
without increasing bleeding, and particularly in trials with
larger populations of lacunar stroke patients.[107]
Cilostazol’s effects on cognition, death and dependency,
and imaging are unclear. In 130 participants with acute
lacunar stroke, the ECLIPSE trial found no difference in
WMH volume change at 90 days between those random-
ized to cilostazol vs. placebo, but did demonstrate that
cilostazol reduced cerebral arterial pulsatility measured
using transcranial Doppler.[119] The small LACI-1 trial
(n= 57) found that cilostazol was well tolerated over a 11
week period in patients with lacunar stroke and was
associated with less progression of WMH as compared
with patients randomised to no cilostazol.[108] The
ongoing LACI-2 trial seeks to assess the effect of cilostazol
on recurrent stroke, cognition, imaging markers of SVD
and death and dependency in 400 participants with prior
lacunar stroke.[109]
Nitric oxide donors
Nitric oxide (NO) and its donors, for example, organic
nitrates (eg, glyceryl trinitrate [GTN] and isosorbide
mononitrate [ISMN]), has multiple effects that might be
beneficial in patients with SVD.[84] TransdermalGTNgiven
within 6 h of stroke onset improved functional outcome and
cognition at 90 days in a subgroup of a large randomized
trial[111];GTNadministeredbetween6and48hoursdidnot
improve outcome.[110] However, when administeredwithin
4 h of stroke onset in the pre-hospital arena in a subsequent
trial, GTN had a neutral effect on clinical outcomes.[120]
Despite, ISMNbeing commonly used in the management of
ischemic heart disease, data regarding its use in SVD and
stroke are scanty. The previously mentioned LACI-1 trial
randomized patients to ISMN, in addition toCilostazol, in a
factorial design. ISMN was well-tolerated and safe, but did
not influence clinical or radiological outcomes in this small
trial.[108] The ongoing LACI-2 trial is also assessing ISMN
and its effects on safety and efficacy in clinical and
radiological outcomes.[109]
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Vitamins
The vitamins of interest in SVD include vitamins B6, B12
and folate. Low levels of B12 have been associated with
more severe WMH.[121] A substudy from the VITATOPS
trial suggested that patients with severe WMH who
received B vitamins for 2 years had slower WMH
progression.[112]
Xanthine oxidase inhibitors
Allopurinol, a xanthine oxidase inhibitor, has multiple
effects that may be beneficial in SVD.[84] A trial of 80
patients with ischemic stroke (1/2 lacunar etiology)
demonstrated reduced BP, augmentation index and carotid
intima-media thickness progression following one year
of receiving allopurinol.[122] Larger trials assessing
allopurinol, including Xilo-FIST (ClinicalTrials.gov:
NCT02122718), are ongoing.
Remote ischemic conditioning
Remote ischemic conditioning (RIC)—transient ischemia
induced to a limb using a BP cuff—has been shown to be
neuroprotective in pre-clinical models.[123] In a small study
of 30 patients with SVD, RIC delivered twice daily for 1
year improved visuospatial and executive function and
reduced WMH compared with sham.[113] The effects of
RIC in lacunar stroke are unclear; the planned RECAST-3
[ISRCTN63231313] and Remote Ischemic Conditioning
in Patients With Acute Stroke [RESIST, NCT03481777]
trials will shed more light on this area.
Discussion and Conclusions
We recommend a holistic, multidisciplinary assessment of
individual needs in patients with suspected SVD. This
includes rigorous management of modifiable risk factors
including smoking cessation, dietary improvements, and
appropriate evidence-based medications while balancing
risks of side effects. In advancing disease, onwards referral
to relevant services should be considered to maximize
independence including cognitive clinics, physiotherapists,
occupational therapists, and social care. We suggest
highlighting awareness of practical issues including
driving, accessible home environments, appointing power
of attorney, and advance care planning. We support close
liaison with patients, family members and general
practitioners to monitor for clinical deterioration. We
note wide variability in choice and definitions of end-
points used in trials in SVD that would benefit from some
standardization. Finally, we advocate for more clinical
trials to identify effective lifestyle and pharmaceutical
interventions.
Future targets for clinical practice and research
We need better recognition of symptoms that best predict
disease progression in longitudinal clinical-imaging-path-
ological studies across healthy, cognitively impaired, and
stroke populations, establishing the natural history of
SVD. Serial imaging studies assessing neuropsychiatric
symptoms are especially lacking. Further work on
interactions between SVD, depression, and their con-
founders will help to clarify the vascular depression
hypothesis. Urinary symptom relationships with SVD
require appropriate adjustment for confounders. Research
should give greater prominence to informants, paralleling
clinical practice.
We need to determine whether widely-accepted clinical
features of subcortical VCI described in early pathological
and CT studies still hold true on longitudinal MRI studies
in VCI populations. How lesion volume, location,
background SVD burden and rate of lesion change interact
with symptoms, cognition, function, and physical and
cognitive reserves needs to be determined. The natural
history of VCI including subcortical subtypes needs to be
better defined, for example, prevalence of stepwise vs.
progressive cognitive decline.
Further work is needed to understand the pathophysiology
of SVD, using advanced preclinical, neuroimaging, and
pathological research methods. We need more trials of
medications and simple lifestyle modifications, or combi-
nations thereof. Further, detailed, observational research
on modifiable and non-modifiable factors is required,
integrating these into clinical trial design, determining
whether using different treatment strategies for individuals
with non-modifiable risk factors produces any additional
benefit.
Integrating approaches to research and clinical care of
patients with SVD
We should empower patients and informants to self-
monitor symptoms, signs, vascular risk factors, and
cognitive test performance, e.g. using mobile phone
applications, virtual clinics, and evolving smart technology
that recognizes alterations in gait or speech patterns. We
should use healthcare encounters to opportunistically seek
features of SVD progression, for example, screening during
vascular risk factor reviews. We should devise electronic
record-based alerts based on notification of relevant
healthcare referrals [Table 1], combined with existing
imaging data.We should devise composite prediction scores
of SVD progression for use as screening tools in everyday
clinical settings, incorporating available symptom, risk
factor, cognitive, demographic, and imaging reports, similar
to those used for estimating cardiovascular or fracture risks.
Efforts to refine an SVDphenotype including, but extending
beyond, stroke and cognitive impairment, are necessary.
Apart from initial identification, we need to recognize those
at the highest risk of SVD progression, tracking which
clinical and imaging features herald progression. This will
allowus to research targeted interventions earlier in the SVD
course, preventing progression before its most disabling
manifestations develop.
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